Paris - Delayed Quote ? EUR Crossject Société Anonyme (ALCJ.PA) Follow Compare 2.0500 -0.0200 (-0.97%) At close: November 1 at 5:35 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE? ahead of filing U.S. Emergency Use Authorization Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file for EUA early next year and to receive a positive FDA response shortly thereafterCrossject will manufacture additional product batches, including first commercial batches in early 2025, in anticipation of first BARDA deliveries later that year Dijon, France, October 22 2024 (07:30 CET) - Crossject (IS GlobeNewswire ? 11 days ago ALCJ.PA -0.97% Crossject announces its eligibility for France’s PEA-PME investment scheme Enables French retail investors to buy securities under preferential tax conditions Dijon, France Sept 26, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO?, today confirms its eligibility for PEA-PME, a French government investment scheme which enables retail investors to acquire a portfolio of European securities whilst benefiting from preferential tax co GlobeNewswire ? last month ALCJ.PA -0.97% Crossject reports financial results and business highlights for the first six months of 2024 Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the Emergency Use Authorization for its epilepsy rescue therapy in early 2025 Dijon, France, September 23, 2024 18:00 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO? auto-injector to deliver life-saving medicines in emergen GlobeNewswire ? last month ALCJ.PA -0.97% Crossject to report first-half 2024 financial results and host webcast on September 23, 2024 Dijon, France, 17 September, 2024 - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO?, will report its financial results for the six months ended June 30, 2024, as scheduled on Monday, September 23. In addition, at 18:00 CET that day, CEO Patrick Alexandre will provide a commentary on the company’s strategic priorities during a webcast and be available for question GlobeNewswire ? last month ALCJ.PA -0.97% Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024 Press Release Dijon, France August 22, 2024 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO?, announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024 in New Yor GlobeNewswire ? 2 months ago ALCJ.PA -0.97% Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE? Epilepsy Rescue Treatment Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE? Epilepsy Rescue Treatment ? Experienced executive to lead preparations for U.S. commercialization of ZEPIZURE?Reinforces and de-risks pre-commercial activities ahead of submitting marketing authorization application for ZEPIZURE? epilepsy rescue treatment in the U.S. Dijon, France August 19, 2024 17:30 CET-- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pha GlobeNewswire ? 2 months ago ALCJ.PA -0.97% Crossject achieves key ZEPIZURE? manufacturing milestone Successful completion of an additional Registration Batch of ZEPIZURE? at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA) Dijon, France, July 18, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of developmen GlobeNewswire ? 3 months ago ALCJ.PA -0.97% Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference Dijon, France, July 15th 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE?, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO?, announces it will attend the H.C. Wainwright 26th Annual Global Investment Conference, taking place in New York September 9-11, 2024. About Crossject Crossject SA (Euronext: ALCJ; www.crossje GlobeNewswire ? 3 months ago ALCJ.PA -0.97% Crossject secures funding from French Government for needle-free platform The cash injection will accelerate the development of Crossject’s prefilled needle-free platform to treat anaphylactic shock. Pharmaceutical Technology ? 3 months ago ALCJ.PA -0.97% Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO? Epinephrine Key contribution to the acceleration of the development of ZENEO? EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies demonstrating outstanding growth and innovation potential Dijon, France, July 10th, 2024 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE?, its emergency treatment for the management of epilept GlobeNewswire ? 3 months ago ALCJ.PA -0.97% Crossject elaborates on ZEPIZURE? potential in light of landmark RAMPART study and its own, recently published, bioequivalence study Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine intravenous (IV)Crossject’s bioequivalence study, recently published in Neurology and Therapy, remarkably consistent with RAMPART’s findings and authors’ views Dijon, France 26 June, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and r GlobeNewswire ? 4 months ago ALCJ.PA -0.97% Crossject appoints Dan Chiche, MD as Chief Medical Officer North America Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes targeting ZEPIZURE? regulatory milestones in the U.S. in 2025 Dijon, France 12 June 2024 , 7:30 am CET- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE?, its emergency treatment for the management of epil GlobeNewswire ? 4 months ago ALCJ.PA -0.97% Crossject announces highly successful closing of its €8 million rights offering Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April 2024 Allows to continue the clinical and regulatory development of ZEPIZURE? until the next value creation milestones, in particular the EUA approval by the FDA Dijon, France 4 April, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces the successful closing of its rights GlobeNewswire ? 4 months ago ALCJ.PA -0.97% Crossject announces publication of clinical data on ZEPIZURE ? in Neurology and Therapy Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum? Early onset can be expected thanks to early blood concentration of midazolam with ZEPIZURE? Low variability confirmed, a key advantage vs other forms of administration, such as intranasal Dijon, France May 30, 2024 -1030 am CET- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of GlobeNewswire ? 5 months ago ALCJ.PA -0.97% Crossject signs a geographic extension of ZEPIZURE? commercialization agreement in Europe Extended contract now covers a total of 11 European countries Crossject will receive milestone payments of up to €1 million in total, upon marketing authorizations Crossject will sell ZEPIZURE? to the partner with a markup that is a share of the gross margin Dijon, France May 02, 2024 -530 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces it has extended the geographic coverage of its 22n GlobeNewswire ? 5 months ago ALCJ.PA -0.97% Crossject reports audited financial results for 2023 Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free auto-injectors technology platform ZENEO?, reports its audited financial results for the year ending December 31, 2023. These results are now available on the Company’s website. Key financial information as of December 31, 2023 Crossject’s financial results for the year ending December 31, 2023 have GlobeNewswire ? 6 months ago ALCJ.PA -0.97% Crossject trading on Euronext to resume as usual on Wednesday April 3 Dijon, France April 2, 2024 – Trading of the stock of Crossject (ISIN: FR0011716265; Euronext: ALCJ) on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET. Crossject’s press release, entitled “Crossject advances in its U.S. Strategy and reports Financial Results for 2023”, was published at 10:30am CET, due to a delay in receiving certain confirmations. For that reason, Crossject required Euronext to stop trading. Following Euronext’s standard procedure in such cases, GlobeNewswire ? 6 months ago ALCJ.PA -0.97% Crossject advances in its U.S. Strategy and reports Financial Results for 2023 Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE? in Q1 2025Expectation to complete U.S. New Drug Application (NDA) for ZEPIZURE? in H1 2025Reinforcement of supply chain [with addition of a second fill-and-finish CDMO]Reporting of a reduced Net loss of €8.5 million versus €11.2 million in 2022 Dijon, France April 2, 2024, 10:30am CET -- Crossject (I GlobeNewswire ? 6 months ago ALCJ.PA -0.97% Crossject gender equality score reaches 96/100 in 2024 Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today announces its EU Gender Equality Index score reached 96/100 for 2024, marking the third successive year it has been above 90%. The Gender Equality Index is a tool to measure the progress of gender equality in the EU, giving more visibility to areas that need improvement and ultimately supporting policy maker GlobeNewswire ? 7 months ago ALCJ.PA -0.97% Crossject obtains a financing up to €12 million, in two tranches Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to €12 million, in two tranches,from an entity managed by Heights Capital Management, in issued bondsconvertible in new shares, with a conversion premium of 35%1, or repayable (in cash and/or stocks, according to the company’s options) over 36 months at a rate of 7%2. CROSSJECT (ISIN: FR0011716265; Stock symbol: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, , announces today th GlobeNewswire ? 8 months ago ALCJ.PA -0.97% Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is CAC 40 Return ALCJ.PA CAC 40 YTD -58.75% -1.78% 1-Year -49.88% +7.60% 3-Year -33.60% +8.47%
